Almost 90% of neuromuscular diseases (NMDs) are classified as rare diseases, defined as conditions affecting less than 5 individuals in 10.000 (0.05%). Their rarity and diversity pose specific challenges for healthcare and research. Epidemiological data on NMDs are often lacking and incomplete. The COVID-19 pandemic has further highlighted the management difficulties of NMDs patients and the necessity to continue the program of implementation of standard of care. This article summarizes the Italian experience during pandemic.

Frailties and critical issues in neuromuscular diseases highlighted by SARS-CoV-2 pandemic: how many patients are still "invisible"?

Mongini T.;
2022-01-01

Abstract

Almost 90% of neuromuscular diseases (NMDs) are classified as rare diseases, defined as conditions affecting less than 5 individuals in 10.000 (0.05%). Their rarity and diversity pose specific challenges for healthcare and research. Epidemiological data on NMDs are often lacking and incomplete. The COVID-19 pandemic has further highlighted the management difficulties of NMDs patients and the necessity to continue the program of implementation of standard of care. This article summarizes the Italian experience during pandemic.
2022
41
1
24
29
COVID-19 pandemic; neuromuscular diseases; Humans; Pandemics; SARS-CoV-2; COVID-19; Frailty; Neuromuscular Diseases
Ricci G.; Torri F.; Bianchi F.; Fontanelli L.; Schirinzi E.; Gualdani E.; Francesconi P.; Gagliardi D.; Serra G.; Mongini T.; Siciliano G.
File in questo prodotto:
File Dimensione Formato  
Ricci G COVID 2022.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 176.76 kB
Formato Adobe PDF
176.76 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1858765
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact